Drugs used in drug-eluting stents (DES) to inhibit proliferation of smooth muscle cells (SMCs) also limit re-endothelialization at the site of stent implantation [1]. Thus, treated patients face an increased risk of late-stent thrombosis. Avoiding this adverse side effect represents one of the major challenges in the design of next-generation DES.
Volume Subject Area:
Poster Session I: Cardiovascular Devices
Topics:
Drugs,
Dynamics (Mechanics),
Stents,
Design,
Muscle,
Risk,
Surface mount components,
Thrombosis
This content is only available via PDF.
Copyright © 2012 by ASME
You do not currently have access to this content.
